Catalyst
Monitor trial results for improvements in LVEF and NYHA classifications, as well as any changes in clinical practice guidelines following the study's outcomes.
Humanexa recommends Monitor.
Date
June 18, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.